Myeloma-Multiple
9
0
2
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
22.2%
2 terminated out of 9 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
125%
5 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
Study of the Immune Response After Vaccination in Multiple Myeloma Patients
Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma
Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma
Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma
Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma
Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma